inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult ≥18 years of age at time of enrollment. 4. subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation. 5. subjects with a positive covid-19 diagnosis by nasal swab or serologic testing. 6. hospitalized with a requirement for supplemental oxygen. 7. have: * either a d- dimer \> 4.0 x uln, or * sepsis-induced coagulopathy (sic) score of ≥4

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult ≥18 years of age at time of enrollment. 4. subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation. 5. subjects with a positive covid-19 diagnosis by nasal swab or serologic testing. 6. hospitalized with a requirement for supplemental oxygen. 7. have: * either a d- dimer \> 4.0 x uln, or * sepsis-induced coagulopathy (sic) score of ≥4

inclusion criteria: subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. understands and agrees to comply with planned study procedures. male or non-pregnant female adult ≥18 years of age at time of enrollment. subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation. subjects with a positive covid-19 diagnosis by nasal swab or serologic testing. hospitalized with a requirement for supplemental oxygen. have: either a d- dimer > 4.0 x uln, or sepsis-induced coagulopathy (sic) score of ≥4

inclusion criteria: subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. understands and agrees to comply with planned study procedures. male or non-pregnant female adult ≥18 years of age at time of enrollment. subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation. subjects with a positive covid-19 diagnosis by nasal swab or serologic testing. hospitalized with a requirement for supplemental oxygen. have: either a d- dimer > 4.0 x uln, or sepsis-induced coagulopathy (sic) score of ≥4

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult ≥18 years of age at time of enrollment. 4. subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation. 5. subjects with a positive covid-19 diagnosis by nasal swab or serologic testing. 6. hospitalized with a requirement for supplemental oxygen. 7. have: - either a d- dimer > 4.0 x uln, or - sepsis-induced coagulopathy (sic) score of ≥4

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult ≥18 years of age at time of enrollment. 4. subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation. 5. subjects with a positive covid-19 diagnosis by nasal swab or serologic testing. 6. hospitalized with a requirement for supplemental oxygen. 7. have: - either a d- dimer > 4.0 x uln, or - sepsis-induced coagulopathy (sic) score of ≥4